WHO, World Bank Say Half The World Population Cannot Access Essential Health Services 13/12/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment According to a report released today by the World Health Organization and the World Bank, at least half the world’s population is lacking access to essential health services. Out of pocket expenses related to health care are pushing millions of people into extreme poverty each year, the report says. Both organisations say they are committed to working with countries to increase access to essential health services.
Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 by Intellectual Property Watch Leave a Comment The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications.
Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 by Tatum Anderson for Intellectual Property Watch 1 Comment The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon.
New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 by Guest contributor for Intellectual Property Watch Leave a Comment What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful.
Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 by Intellectual Property Watch 2 Comments A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. The delegation sat down with Intellectual Property Watch’s Catherine Saez to talk about their Geneva visit.
WHO Issues Two Reports Detailing Global Problem Of Substandard And Falsified Medicines 28/11/2017 by William New, Intellectual Property Watch Leave a Comment The World Health Organization today issued two substantive reports on the problem of substandard and falsified medicines around the world, finding among other things that an estimated one in 10 medical products in low and middle income countries is either substandard or falsified.
Expert Panel Recommends That The WHO Move Forward On Transparency And Delinkage 28/11/2017 by Guest contributor for Intellectual Property Watch Leave a Comment On Monday, 27 November, the WHO published the recommendations of the overall programme review of the global strategy and plan of action on public, health innovation and intellectual property (EB142/14). The expert panel provided 33 recommendations which included 17 forward looking”high-priority actions” including on transparency and delinkage, writes Thiru Balasubramaniam.
TWN – Proposed WHO Criteria On Medicines In Transit Open Door For Seizures 28/11/2017 by Intellectual Property Watch Leave a Comment Geneva, 21 Nov (TWN) – A discussion document prepared by the Secretariat of the World Health Organization (WHO) proposes criteria to justify interventions with respect to medicines in transit. This document is prepared for the 6th meeting of the Member State Mechanism (MSM) to be held from 28 November to 1 December at the WHO headquarters in Geneva, writes Third World Network.
Access To Affordable Healthcare: A Global Wake-Up Call Fosters Coalition Of The Like-Minded 27/11/2017 by Patralekha Chatterjee for Intellectual Property Watch Leave a Comment NEW DELHI — Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue.
‘The WHO Does Not Have A Board’: New WHO Director Pushes To Make Agency More Efficient 24/11/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment World Health Organization Director General Tedros Adhanom Ghebreyesus (Tedros) admonished member states at the close of this week’s special session of the WHO Executive Board charged with examining the agency’s draft work programme for 2019-2023. A trust deficit among member states leads to the multiplication of national statements, impeding efficiency, he said. Meanwhile, a number of countries called for affordable and accessible medicines, and help to manufacture generic medicines locally, while the United States pushed the role of the private sector.